Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Androgens drive prostate cancer (PCa) and are key treatment targets for advanced disease.
• Therapy resistance leads to metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine disease (tNEPC).
• DNA methylome instability is a hallmark of PCa development and progression.

Purpose of the Study:

• To investigate DNA methylation dynamics during the transition from castration-sensitive to tNEPC states.
• To identify novel mechanisms of therapeutic resistance in advanced prostate cancer.
• To explore potential methylation biomarkers in circulating cell-free DNA (cfDNA) for disease progression.

Main Methods:

• Genome-wide methylation analysis was performed on a xenograft model of castration-resistant prostate cancer (CRPC).
• Analysis included cell lines representing various stages of PCa progression.
• Combined analysis of methylation and gene expression data was conducted.

Main Results:

• Extensive methylation changes were confirmed during the development of CRPC and tNEPC.
• Key genes and pathways involved in cellular differentiation and neurodevelopment showed altered methylation.
• tNEPC-related methylation signals were detected in cfDNA from mCRPC patients and correlated with faster progression.

Conclusions:

• DNA methylation dynamics are critical in PCa progression and the development of treatment resistance.
• Identified genes and methylation patterns may serve as novel therapeutic targets and predictive biomarkers.
• cfDNA methylation signals show promise for identifying patients with aggressive mCRPC.